Principal Investigator
Janaki Sharma
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20240979
Clinical Trial Summary
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy
Phase
Phase III
Funding Agency/Sponsor
Industrial
Disease
Prostate, Bladder, and Kidney Cancers
Contact Information
Phone Number
305-243-2647